See more : PowerCell Sweden AB (publ) (PCELL.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Nevro Corp. (NVRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nevro Corp., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- iomart Group plc (IOM.L) Income Statement Analysis – Financial Results
- Jiamei Food Packaging (Chuzhou) Co.,Ltd (002969.SZ) Income Statement Analysis – Financial Results
- Pacific Oak Strategic Opportunity REIT, Inc. (PCOK) Income Statement Analysis – Financial Results
- Prelude Therapeutics Incorporated (PRLD) Income Statement Analysis – Financial Results
- Vega Corporation Co.,Ltd. (3542.T) Income Statement Analysis – Financial Results
Nevro Corp. (NVRO)
About Nevro Corp.
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 425.17M | 406.37M | 386.91M | 362.05M | 390.26M | 387.29M | 326.67M | 228.50M | 69.61M | 32.57M | 23.50M | 18.15M |
| Cost of Revenue | 135.11M | 130.00M | 120.86M | 112.15M | 121.91M | 113.97M | 98.98M | 75.43M | 28.12M | 11.28M | 9.47M | 7.53M |
| Gross Profit | 290.06M | 276.37M | 266.04M | 249.90M | 268.35M | 273.32M | 227.69M | 153.07M | 41.49M | 21.30M | 14.03M | 10.62M |
| Gross Profit Ratio | 68.22% | 68.01% | 68.76% | 69.02% | 68.76% | 70.57% | 69.70% | 66.99% | 59.60% | 65.38% | 59.69% | 58.53% |
| Research & Development | 54.42M | 53.07M | 47.67M | 45.60M | 59.02M | 48.46M | 37.56M | 33.73M | 21.38M | 19.82M | 20.35M | 15.66M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 266.61M | 219.71M | 142.42M | 82.47M | 29.78M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 334.70M | 322.14M | 309.31M | 267.15M | 305.81M | 266.61M | 219.71M | 142.42M | 82.47M | 29.78M | 18.83M | 14.09M |
| Other Expenses | 246.00K | 511.00K | -814.00K | -495.00K | -697.00K | -1.16M | 1.07M | -1.10M | -1.74M | -1.88M | -654.00K | 186.00K |
| Operating Expenses | 389.37M | 375.20M | 356.98M | 312.75M | 364.83M | 315.07M | 257.27M | 176.15M | 103.85M | 49.60M | 39.18M | 29.75M |
| Cost & Expenses | 524.48M | 505.20M | 477.84M | 424.90M | 486.73M | 429.03M | 356.25M | 251.59M | 131.97M | 60.88M | 48.65M | 37.28M |
| Interest Income | 14.17M | 4.02M | 671.00K | 2.96M | 6.02M | 4.87M | 3.16M | 1.69M | 575.00K | 0.00 | 153.00K | 139.00K |
| Interest Expense | 8.01M | 6.43M | 19.75M | 21.81M | 10.93M | 10.40M | 9.90M | 6.39M | 2.73M | 16.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 11.54M | 10.33M | 8.68M | 8.19M | 7.80M | 3.89M | 2.51M | 1.72M | 614.00K | 96.00K | 47.00K | 39.00K |
| EBITDA | -78.31M | 21.02M | -102.40M | -52.21M | -83.36M | -37.86M | -22.84M | -22.04M | -62.92M | -30.09M | -25.10M | -19.09M |
| EBITDA Ratio | -18.42% | -50.16% | -18.33% | -17.36% | -24.72% | -10.78% | -9.05% | -9.55% | -89.60% | -86.90% | -106.83% | -105.18% |
| Operating Income | -99.31M | -98.84M | -90.93M | -62.85M | -96.48M | -41.74M | -29.58M | -23.08M | -62.37M | -28.31M | -25.15M | -19.13M |
| Operating Income Ratio | -23.36% | -24.32% | -23.50% | -17.36% | -24.72% | -10.78% | -9.05% | -10.10% | -89.60% | -86.90% | -107.03% | -105.40% |
| Total Other Income/Expenses | 1.45M | -1.90M | -19.89M | -19.35M | -5.61M | -6.69M | -5.67M | -7.07M | -3.90M | -1.90M | -501.00K | 325.00K |
| Income Before Tax | -97.86M | 4.26M | -130.83M | -82.20M | -102.09M | -48.44M | -35.25M | -30.16M | -66.27M | -30.20M | -25.65M | -18.81M |
| Income Before Tax Ratio | -23.02% | 1.05% | -33.81% | -22.70% | -26.16% | -12.51% | -10.79% | -13.20% | -95.20% | -92.72% | -109.16% | -103.61% |
| Income Tax Expense | -5.65M | 1.26M | 534.00K | 868.00K | 1.60M | 768.00K | 1.41M | 1.62M | 1.17M | 478.00K | 362.00K | 162.00K |
| Net Income | -92.21M | 3.00M | -131.36M | -83.07M | -103.69M | -49.21M | -36.66M | -31.78M | -67.43M | -30.68M | -26.01M | -18.97M |
| Net Income Ratio | -21.69% | 0.74% | -33.95% | -22.94% | -26.57% | -12.70% | -11.22% | -13.91% | -96.88% | -94.19% | -110.70% | -104.50% |
| EPS | -2.56 | 0.09 | -3.77 | -2.47 | -3.37 | -1.64 | -1.25 | -1.12 | -2.54 | -6.91 | -38.27 | -27.90 |
| EPS Diluted | -2.56 | 0.08 | -3.77 | -2.47 | -3.37 | -1.64 | -1.25 | -1.12 | -2.54 | -6.91 | -38.27 | -27.90 |
| Weighted Avg Shares Out | 35.98M | 35.32M | 34.82M | 33.68M | 30.80M | 30.05M | 29.42M | 28.49M | 26.58M | 4.44M | 679.77K | 679.77K |
| Weighted Avg Shares Out (Dil) | 35.98M | 35.53M | 34.82M | 33.68M | 30.80M | 30.05M | 29.42M | 28.49M | 26.58M | 4.44M | 679.77K | 679.77K |
Here's Why You Should Retain Nevro (NVRO) Stock for Now
Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
Nevro1™ Proven to Immediately Transfix Sacroiliac (SI) Joint to Allow for Long-term SI Joint Fusion REDWOOD CITY, Calif. , Feb. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of...
Why Nevro Stock Lagged the Market on Thursday
Despite convincing beats on its latest set of quarterly figures, the market wasn't all that impressed with the company's latest developments.
Nevro's (NVRO) Q4 Earnings and Sales Top Estimates, Margins Up
Nevro's (NVRO) fourth-quarter earnings and revenues surpass their respective consensus estimate. The company incurs a loss in the operating level.
Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript
Nevro Corp. (NVRO) Q4 2023 Earnings Call Transcript
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
Nevro (NVRO) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.54 per share a year ago.
Nevro Enters Into Cooperation Agreement With Engaged Capital
Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif.
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
Provides Full-Year and First-Quarter 2024 Guidance REDWOOD CITY, Calif. , Feb. 21, 2024 /PRNewswire/ --Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and...
Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Source: https://incomestatements.info
Category: Stock Reports